MedTrace Logo

Gamma Scintigraphy Study to Investigate Tablet Disintegration in Healthy Volunteers.

NCT03497715 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-04-13

No results posted yet for this study

Summary

The study will be an adaptive, 2 part, single dose, 5-way crossover gamma scintigraphy study in healthy subjects, to investigate the rate and site of tablet disintegration of various forms of Ibuprofen.

Conditions

  • Healthy Subjects

Interventions

DRUG

Ibuprofen lysine

Test 1

DRUG

Ibuprofen Sodium

Test 2

DRUG

Ibuprofen

Test 3

DRUG

Ibuprofen (Nurofen)

Reference 1

DRUG

Ibuprofen (Wockhardt)

Reference 2

Sponsors & Collaborators

  • Reckitt Benckiser Healthcare (UK) Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-14
Primary Completion
2015-07-30
Completion
2015-07-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03497715 on ClinicalTrials.gov